Drug intelligence / Profile preview

ProTrans-Repeat

Development stage: Unknown
Lead developer: NextCell Pharma
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ProTrans-Repeat is an investigational cell therapy developed by NextCell Pharma, utilizing umbilical cord-derived mesenchymal stromal cells (MSCs). It is specifically designed for the treatment of Type 1 diabetes (T1D). The Repeat designation refers to a clinical development program evaluating the safety and efficacy of a second dose of ProTrans in patients who had previously participated in the ProTrans-1 and ProTrans-2 trials. The therapy functions by modulating the patient's immune system to halt or delay the autoimmune destruction of insulin-producing beta cells in the pancreas, thereby preserving endogenous insulin production and reducing the need for exogenous insulin.

Brand names: ProTrans
Other names: ProTrans-Repeat study

Beyond the preview

Go deeper on ProTrans-Repeat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProTrans-Repeat.

Explore the full profile